Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Clinical trial NCT04410991 · COMPLETED

Trial details

NCT number: NCT04410991
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsing Multiple Sclerosis

Start date: 2020-06-11
Primary completion: 2024-07-16
Enrollment: 899

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.